Study of ALN-PNP with or without tirzepatide for fatty liver disease
Treatments studied
Part of Digestive system clinical trials.
This trial tests a new drug, ALN-PNP, alone or with tirzepatide in people with a specific genetic type of fatty liver disease. It aims to see if the combination reduces liver fat.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have the PNPLA3 p.I148M gene change (both copies).
- Your liver fat must be at least 15% on a special MRI scan.
- You need a body mass index (BMI) between 30 and 45.
- If you are in Part A, you must already be taking a stable dose of tirzepatide (at least 5 mg weekly).
- You cannot have cirrhosis or other chronic liver diseases.
- You must be able to have an MRI (no metal implants, no severe claustrophobia).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests whether ALN-PNP is safe and well tolerated, first in healthy adults and then in adults with MASLD (fatty liver disease). If you have MASLD, it may help researchers learn whether this medicine is a promising option for treating liver fat buildup.
This study tests a new drug called ALN-CIDEB for people with fatty liver disease (MASLD or MASH). The goal is to see if it can reduce liver fat and improve liver health. You may qualify if you have a higher BMI and evidence of liver fat on imaging tests.
This Phase 2 study tests a gene-silencing treatment to improve chronic liver disease called MASH, especially in people with certain genetic risk. You may be eligible if you have MASH with moderate-to-advanced scarring and specific test results, and if other liver causes and recent substance/alcohol issues don’t apply.
This study is testing whether advanced imaging and other non-invasive methods can properly identify people with significant liver scarring due to metabolic liver disease or alcohol-related liver disease. It may help find better ways to track liver health without repeated needle biopsies.
This study tests whether a new drug called AZD2389 is safe and well-tolerated in adults with steatotic liver disease (fatty liver) that has progressed to advanced scarring. The trial aims to see if this drug might help slow or improve liver damage in people with this condition.
This trial tests if tirzepatide, a diabetes and weight loss medication, can help improve fatty liver disease in people who are overweight or have obesity. It may offer a new treatment option for managing liver health.
Hear when a new Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.